Private equity firm THL Partners acquires Headlands Research, a global clinical trial site network, for around $600m. The deal aims to boost Headlands Research’s growth and technology infrastructure to enhance medical therapy development for biotech and pharma sponsors. Headlands Research specializes in various therapeutic areas and uses a data-driven model to broaden trial access.

Established in 2018 by KKR, Headlands Research focuses on enhancing study inclusivity in clinical trials. The acquisition by THL through Fund IX is expected to close this year pending customary conditions. Legal counsel for the transaction was provided by McDermott Will & Schulte, Paul, Weiss, Rifkind, Wharton & Garrison, and financial advice by Jefferies.

Headlands Research CEO Kyle Burtnett expresses gratitude to KKR for their support, emphasizing the partnership’s success in advancing medical research. The company looks forward to collaborating with THL to drive clinical trial innovation and build on the strong foundation in place. Over 5,000 clinical studies have been completed by Headlands Research, showcasing its expertise in the field.

In a strategic move, THL Partners agrees to acquire Headlands Research, a prominent clinical trial site firm, to accelerate clinical trial innovation. The acquisition aligns with Headlands Research’s goal of advancing medical therapies and expanding access to clinical trials for underrepresented subject groups. The transaction is set to close this year, pending customary conditions.

Read more at Yahoo Finance: THL Partners agrees to acquire clinical trial site firm Headlands Research